Home GPCR & G Protein SGLT

SGLT Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S8637 Ipragliflozin (ASP1941) Ipragliflozin (ASP1941) is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor with an IC50 value of 7.4 nM for hSGLT2 and a 254-fold selectivity versus SGLT1.
E0910New Swertisin Swertisin is a C-glucosylflavone isolated from Swertia japonica, an antagonist of adenosine A1 receptor and an inhibitor of SGLT2, also exhibiting strong inhibitory effects on HBsAg, HBeAg, and HBV DNA both in vitro and in vivo. It also exhibits antidiabetic, anti-inflammatory and antioxidant effects shows promising applications in diabetes, inflammation, schizophrenia, and HBV-related disease research.
S8938 KGA-2727 KGA-2727 is a potent, selective, high-affinity inhibitor of sodium glucose cotransporter 1 (SGLT1) with Ki of 97.4 nM and 43.5 nM for human SGLT1 and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of this compound are 140 (human) and 390 (rat). This chemical exhibits antidiabetic efficacy in rodent models.
S8939 Mizagliflozin (KWA 0711, DSP-3235 free base) Mizagliflozin (KWA 0711) is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation.
S5413 Ertugliflozin Ertugliflozin (MK-8835, PF-04971729) is a potent and selective sodium-dependent glucose cotransporter 2 inhibitor with IC50 values of 0.877 nM for h-SGLT2 and 1000-fold higher for h-SGLT1.
E0141 Bexagliflozin (EGT1442)

Bexagliflozin (EGT1442, EGT-0001442, THR-1442) is a potent and selective SGLT2 inhibitor with an IC50 of 2 nM.
S4431 Ertugliflozin L-pyroglutamic acid Ertugliflozin (MK-8835, PF-04971729) L-pyroglutamic acid is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2) with IC50 of 0.877 nM for h-SGLT2. Ertugliflozin has the potential for the treatment of type 2 diabetes mellitus.